Search Results - "Robert Straubinger"

Pharmacodynamic Drug–Drug Interactions by Niu, Jin, Straubinger, Robert M., Mager, Donald E.

“…Pharmacodynamic drug–drug interactions (DDIs) occur when the pharmacological effect of one drug is altered by that of another drug in a combination regimen…”
Get full text

Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces Cancer Cell Death via Metabolic Remodeling and Activation of the Extrinsic Apoptosis Pathway by Rasam, Sailee, Lin, Qingxiang, Shen, Shichen, Straubinger, Robert M, Qu, Jun

“…Pancreatic cancer patients have poor survival rates and are frequently treated using gemcitabine (Gem). However, initial tumor sensitivity often gives way to…”
Get full text

Species-Deconvolved Proteomics for In Situ Investigation of Tumor-Stroma Interactions after Treatment of Pancreatic Cancer Patient-Derived Xenografts with Combined Gemcitabine and Paclitaxel by Wang, Xue, Niu, Jin, Qian, Shuo, Shen, Shichen, Straubinger, Robert M., Qu, Jun

“…Tumor-stroma interactions are critical in pancreatic ductal adenocarcinoma (PDAC) progression and therapeutics. Patient-derived xenograft (PDX) models…”
Get full text

Current taxane formulations and emerging cabazitaxel delivery systems by Sun, Boyang, Straubinger, Robert M., Lovell, Jonathan F.

“…Cabazitaxel is a second-generation taxane with promising anti-tumor activity and is approved for treating hormone-refractory metastatic prostate cancer…”
Get full text

Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer by Vaidya, Tanaya, Straubinger, Robert M., Ait-Oudhia, Sihem

“…Purpose Trastuzumab combined with Doxorubicin (DOX) demonstrates significant clinical activity in human epidermal growth factor receptor-2 (HER2)-positive…”
Get full text

Systems pharmacodynamic model of combined gemcitabine and trabectedin in pancreatic cancer cells. Part I.Çô Effects on signal transduction pathways related to tumor growth by Miao, Xin, Shen, Shichen, Koch, Gilbert, Wang, Xue, Li, Jun, Shen, Xiaomeng, Qu, Jun, Straubinger, Robert M, Jusko, William J

“…Pancreatic ductal adenocarcinoma (PDAC) is often chemotherapy-resistant, and novel drug combinations would fill an unmet clinical need. Previously we reported…”
Get more information

Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model by Wang, Jun, Chan, Darren K W, Sen, Arindam, Ma, Wen Wee, Straubinger, Robert M

“…Despite frequent overexpression of numerous growth factor receptors by pancreatic ductal adenocarcinomas (PDAC), such as EGFR, therapeutic antibodies have not…”
Get full text

Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition by Moloney, Cara, Chaudhuri, Tista Roy, Spernyak, Joseph A., Straubinger, Robert M., Brougham, Dermot F.

“…Nanocarriers are candidates for cancer chemotherapy delivery, with growing numbers of clinically-approved nano-liposomal formulations such as Doxil® and…”
Get full text

Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer by Lin, Qingxiang, Serratore, Andrea, Perri, Jonathan, Roy Chaudhuri, Tista, Qu, Jun, Ma, Wen Wee, Kandel, Eugene S, Straubinger, Robert M

“…Elevated fibroblast growth factor receptor (FGFR) activity correlates with pancreatic adenocarcinoma (PDAC) progression and poor prognosis. However, its…”
Get full text

Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals by Luo, Dandan, Carter, Kevin A., Molins, Emilie A.G., Straubinger, Ninfa L., Geng, Jumin, Shao, Shuai, Jusko, William J., Straubinger, Robert M., Lovell, Jonathan F.

“…Chemophototherapy (CPT) merges photodynamic therapy with chemotherapy and can substantially enhance drug delivery. Using a singular liposomal formulation for…”
Get full text

Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology by Ait-Oudhia, Sihem, Mager, Donald E, Straubinger, Robert M

“…Liposomal formulations of anticancer agents have been developed to prolong drug circulating lifetime, enhance anti-tumor efficacy by increasing tumor drug…”
Get full text

Formation of hydrated PEG layers on magnetic iron oxide nanoflowers shows internal magnetisation dynamics and generates high in-vivo efficacy for MRI and magnetic hyperthermia by McKiernan, Eoin P., Moloney, Cara, Roy Chaudhuri, Tista, Clerkin, Shane, Behan, Kevin, Straubinger, Robert M., Crean, John, Brougham, Dermot F.

“…Multicore magnetic iron oxide nanoparticles, nanoflowers (NFs), have potential biomedical applications as efficient mediators for AC-magnetic field…”
Get full text

Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation by Lin, Qingxiang, Qian, Zhicheng, Jusko, William J, Mager, Donald E, Ma, Wen Wee, Straubinger, Robert M

“…Median survival of pancreatic ductal adenocarcinoma cancer (PDAC) is 6 months, with 9% 5-year survival. Standard-of-care gemcitabine (Gem) provides only modest…”
Get full text

Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer by Lin, Qingxiang, Shen, Shichen, Qian, Zhicheng, Rasam, Sailee S., Serratore, Andrea, Jusko, William J., Kandel, Eugene S., Qu, Jun, Straubinger, Robert M.

“…Pancreatic adenocarcinoma (PDAC) is highly refractory to treatment. Standard-of-care gemcitabine (Gem) provides only modest survival benefits, and development…”
Get full text

Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours by McDaid, William J, Greene, Michelle K, Johnston, Michael C, Pollheimer, Ellen, Smyth, Peter, McLaughlin, Kirsty, Van Schaeybroeck, Sandra, Straubinger, Robert M, Longley, Daniel B, Scott, Christopher J

“…The anti-Epidermal Growth Factor Receptor (EGFR) antibody Cetuximab (CTX) has demonstrated limited anti-cancer efficacy in cells overexpressing EGFR due to…”
Get more information

Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness by Lin, Qingxiang, Serratore, Andrea, Niu, Jin, Shen, Shichen, Roy Chaudhuri, Tista, Ma, Wen Wee, Qu, Jun, Kandel, Eugene S., Straubinger, Robert M.

“…Pancreatic ductal adenocarcinoma (PDAC) is often intrinsically-resistant to standard-of-care chemotherapies such as gemcitabine. Acquired gemcitabine…”
Get full text

Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells by Miao, Xin, Koch, Gilbert, Straubinger, Robert M., Jusko, William J.

“…Purpose This study investigates the combined effects of gemcitabine and trabectedin (ecteinascidin 743) in two pancreatic cancer cell lines and proposes a…”
Get full text

Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors by Roy Chaudhuri, Tista, Lin, Qingxiang, Stachowiak, Ewa K, Rosario, Spencer R, Spernyak, Joseph A, Ma, Wen Wee, Stachowiak, Michal K, Greene, Michelle K, Quinn, Gerard P, McDade, Simon S, Clynes, Martin, Scott, Christopher J, Straubinger, Robert M

“…Paracrine activation of pro-fibrotic hedgehog (HH) signaling in pancreatic ductal adenocarcinoma (PDAC) results in stromal amplification that compromises tumor…”
Get full text

Single-treatment tumor ablation with photodynamic liposomal irinotecan sucrosulfate by Ghosh, Sanjana, Sun, Boyang, Jahagirdar, Dushyant, Luo, Dandan, Ortega, Joaquin, Straubinger, Robert M., Lovell, Jonathan F.

“…•A liposomal formulation of irinotecan that contains a non-exchangeable, embedded photosensitizer gives rise to enhanced serum stability and rapid…”
Get full text

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells by Niu, Jin, Wang, Xue, Qu, Jun, Mager, Donald E, Straubinger, Robert M

“…For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX),…”
Get full text